Advocate Health Care Renews Multi-Year, System-Wide Contract for Masimo SET(R) Pulse Oximetry Technology
IRVINE, Calif., Nov. 23 /PRNewswire-FirstCall/ — Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Advocate Health Care–Illinois’ largest health care provider–has renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology. A Masimo customer since 2001, Advocate Health Care’s renewal of its Masimo SET technology standardization contract means Masimo will continue to support the pulse oximetry needs of more than 200 Advocate sites of care across metropolitan Chicago.
Masimo SET pulse oximetry technology allows hospitals and other care sites to leverage the superior Measure-Through Motion and Low-Perfusion benefits of Masimo SET pulse oximetry, along with the unique breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry. Masimo Rainbow SET is the first-and-only technology platform capable of continuously and noninvasively measuring multiple blood constituents that previously required invasive procedures, including: total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCOÃ‚®), methemoglobin (SpMetÃ‚®), and PVIÃ‚®, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI). The ability to immediately detect and treat potentially life-threatening conditions–without having to draw blood and wait for the results–enables earlier and better clinical decisions that may help save lives and improve patient outcomes.
“Advocate Health Care’s healing mission calls us to work with partners that share our commitment to our patients’ health and safety,” said Paul Hoffmann, R.R.T., chairman of the Advocate Health Care respiratory care council. “We are very satisfied with the features and functionality of the Masimo pulse oximetry technology, and we are pleased to continue our relationship with Masimo.”
Masimo Founder and CEO, Joe E. Kiani, stated, “Advocate Health is one of the premier health care institutions in the US. We are proud to have earned Advocate’s trust over the last eight years and that they have decided to place their trust, business, and pulse oximetry needs in our hands for many more years.”
Advocate Health Care, one of the nation’s top 10 health systems based on clinical performance, is the largest health care provider in Illinois. As a not-for-profit, mission-based health system, Advocate operates more than 200 sites of care across metropolitan Chicago, including nine acute care hospitals, two children’s hospitals, four Level I trauma centers (the state’s highest designation in trauma care), a home health care company and one of the region’s largest medical groups.
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care–helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SETÃ‚®, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO(2) and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SETÃ‚® Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCOÃ‚®), methemoglobin (SpMetÃ‚®), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of “Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.” Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that Masimo SET and Masimo Rainbow SET will provide sufficient sensitivity and specificity to detect physiological abnormalities in real-time, enabling clinicians to detect and identify potentially life-threatening conditions earlier and make better clinical and treatment decisions that may help save lives and improve outcomes for their patients, risks related to our assumption that Masimo SET and Masimo Rainbow SET will deliver a sufficient level of clinical improvement over alternative pulse oximetry and noninvasive patient monitoring technologies to allow for further adoption of the technology at other hospitals, risks related to our assumption that the system-wide renewal of Advocate Health Care will serve to substantially increase revenues, and risks related to our assumptions regarding the future of the Advocate Health Care system-wide pulse oximetry renewal contract, as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC“), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Media Contacts: Dana Banks Kelly Jo Golson Masimo Corporation Advocate Health Care (949) 297-7348 (630) 990-5615 email@example.com firstname.lastname@example.org
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.